Paolo Tarantino, Advanced Research Fellow at Dana-Farber Cancer Institute, shared a post on X about a paper by Shani Paluch-Shimon et al. published in Nature Reviews Clinical Oncology:
“Interesting commentary on one of the most relevant and debated recent studies in breast oncology: SONIA. Are the results compelling enough to consider a delayed administration of CDK4/6-inhibitors for HR+/HER2- MBC?”
“The SONIA trial shows the power and challenges of academic research”
Authors: Shani Paluch-Shimon, Fatima Cardoso.
More posts featuring Paolo Tarantino.